Enveda raises $311M for AI-derived drugs
Biotech Enveda secures $311 million for clinical trials.
Published 1j1 sourceNotable
Lire en français
≈ 14s
The fact
The company, valued at $2 billion, targets skin conditions and weight preservation.
Two drugs are already in testing with volunteers.
Click the link to read an article on the topic: